IL6 and acute respiratory distress syndrome: To stop this inflammatory process that is harmful to the patient, some studies (Wu R et al., 2020; Xu et al., 2020; REMAP-CAP Investigators, 2021) have shown that blocking (tocilizumab or sarilumab) of IL-6 functions promotes a significant clinical improvement and better prognosis for COVID-19 patients with ARDS.